Reven Pharmaceuticals Reven Pharmaceuticals
homepage 2017-11-29T10:03:28+00:00

Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction – Full Text View – ClinicalTrials.gov

Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction – Full Text View – ClinicalTrials.gov

REVEN

is a global healthcare company with more than

10 years of innovation and leadership in vascular care.

TELL ME MORE > Product Pipeline >

On January 15, 2019 Reven completed their single-ascending-dose (SAD)/ multiple-ascending-dose (MAD) Phase 1 Clinical Trial in the United States. Reven is now in the planning stage of their Phase 2 Clinical Trial that will be conducted in the United States in Q2 of 2019.